A Phase 1 Study to Assess Safety and Effectiveness of BAY 3547926 in Adults with Advanced Liver Cancer Showing Glypican 3 Protein

What this Trial Is About

Researchers are studying a new drug called BAY 3547926 in people with advanced liver cancer known as hepatocellular carcinoma HCC that shows a specific protein called Glypican 3 GPC3. This is the first time BAY 3547926 is being tested in humans, aiming to understand its safety, how the body processes it, and to find the best dose for treating this advanced cancer. The study also explores how well the drug works to fight the cancer. BAY 3547926 is an antibody conjugate labeled with a radioactive agent that targets cancer cells directly. This radioactive part emits radiation that damages and kills cancer cells with minimal harm to nearby healthy tissues. Participants will be part of one of four study parts the first part tests different doses to identify a safe and effective level once found, more participants will receive that dose alone or with other treatments in the following parts. During the study, participants will have health check-ups and scans to monitor their condition. Blood and urine samples will be collected, and participants will be asked about their health and any problems they experience. The research team will watch for side effects and measure how the cancer responds to the treatment over a period of up to 60 months after the first dose.

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer